Symposium | ECP for chronic GvHD: Patient eligibility, treatment optimization, and follow-up

On April 14, 2024, the GvHD Hub held a symposium at the 50th European Society for Bone and Marrow Transplantation (EBMT) Annual Meeting on the role of extracorporeal photopheresis (ECP) in the management of chronic graft-versus-host disease (cGvHD).

Zinaida Perić, University of Rijeka, Rijeka, HR, shared her thoughts on patient eligibility, treatment optimization, and follow-up after treatment with ECP for cGvHD. She also discussed a case report of a patient with steroid-refractory (SR)-cGvHD, plus retrospective (Table 1) and prospective data on the use of ECP in cGvHD. In addition, she shared the Nordic ECP Quality Group treatment guidelines for SR-cGvHD.

Table 1. Retrospective data of ECP in SR-cGvHD*

ECP, extracorporeal photopheresis; SR-cGvHD, steroid-resistant chronic graft-versus-host disease.
*Data from Nygaard et al.¹

Figure 1. Treatment guidelines proposed by the Nordic ECP Quality Group*

cGvHD, chronic graft-versus-host disease; CR, complete response; ECP, extracorporeal photopheresis; MR, minimal response; mixR, mixed response; NC, no change; PR, partial response; SR, steroid-refractory.
*Adapted from Lee et al.²

Listen to this presentation as a podcast here:

Q&A session

This symposium closed with a panel Q&A session with live audience participation, where our panelists discussed their perspectives on donor lymphocyte infusion post-transplant, and treatment routes if GvHD develops.

This independent educational activity was supported by Mallinckrodt Pharmaceuticals. All content was developed independently by the faculty. The funder was allowed no influence on the content of this activity.